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The tumor suppressor miR‑642a‑5p
targets Wilms Tumor 1 gene
and cell‑cycle progression
in prostate cancer
Dianne J. Beveridge1,2,5, Kirsty L. Richardson1,2,5, Michael R. Epis1,2,5, Rikki A. M. Brown1,2,
Lisa M. Stuart1,2, Andrew J. Woo1,2,3 & Peter J. Leedman1,2,4*
RNA-based therapeutics are emerging as innovative options for cancer treatment, with microRNAs
being attractive targets for therapy development. We previously implicated microRNA-642a-5p
(miR-642a-5p) as a tumor suppressor in prostate cancer (PCa), and here we characterize its mode of
action, using 22Rv1 PCa cells. In an in vivo xenograft tumor model, miR-642a-5p induced a significant
decrease in tumor growth, compared to negative control. Using RNA-Sequencing, we identified
gene targets of miR-642a-5p which were enriched for gene sets controlling cell cycle; downregulated
genes included Wilms Tumor 1 gene (WT1), NUAK1, RASSF3 and SKP2; and upregulated genes
included IGFBP3 and GPS2. Analysis of PCa patient datasets showed a higher expression of WT1,
NUAK1, RASSF3 and SKP2; and a lower expression of GPS2 and IGFBP3 in PCa tissue compared to
non-malignant prostate tissue. We confirmed the prostatic oncogene WT1, as a direct target of miR642a-5p, and treatment of 22Rv1 and LNCaP PCa cells with WT1 siRNA or a small molecule inhibitor
of WT1 reduced cell proliferation. Taken together, these data provide insight into the molecular
mechanisms by which miR-642a-5p acts as a tumor suppressor in PCa, an effect partially mediated by
regulating genes involved in cell cycle control; and restoration of miR-642-5p in PCa could represent a
novel therapeutic approach.
Abbreviations
miRNA	MicroRNA
PCa	Prostate cancer
RNA-Seq	RNA-sequencing
3′UTR	3′Untranslated region
siRNA	Small interfering RNA
RT-qPCR	Reverse transcription and quantitative polymerase chain reaction
DOHH	Deoxyhypusine hydroxylase
WT1	Wilms Tumor 1 gene
NUAK1	NUAK family SNF1-like kinase 1
RASSF3	Ras association domain family member 3
SKP2	S-phase kinase-associated protein 2
GPS2	G Protein Pathway Suppressor 2
IGFBP3	Insulin-like growth factor-binding protein 3
17-AAG	17-(Allylamino)-17-demethoxygeldanamycin (Tanespimycin)
Prostate cancer (PCa) is the second most diagnosed cancer worldwide accounting for 3.8% of cancer related death
in men1. PCa diagnoses have increased in recent years, which is attributable to both the broader awareness of
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the disease, improved detection methods, and the emergence of screening for biomarkers (e.g. Prostate-Specific
Antigen (PSA))2. There has also been a significant increase in the early diagnosis of localized, low-risk PCa, ranging from 10 to 80% of all men diagnosed with PCa w
 orldwide3, with a subsequent decrease in PCa m
 ortality4. A
sizeable proportion of men with low-risk PCa are carefully monitored via active surveillance and do not require
treatment or surgery5,6. PCa growth is initially androgen-dependant via the expression of the androgen receptor
(AR), providing the basis for androgen deprivation therapies. In the last decade, the development of multiple
drugs that target the androgen axis has improved the survival of PCa patients, including Abiraterone Acetate
and Enzalutamide7–9. Unfortunately in many men, the disease transforms into hormone refractory or castrate
resistant prostate cancer (CRPC), whereby tumors become increasingly resistant to conventional AR pathway
inhibitor treatments characterized by metastasis and premature death10,11. Thus, there remains a large unmet
clinical need to develop novel approaches to treat PCa, especially advanced CRPC.
MicroRNAs (miRNAs) are a family of ~ 22 nucleotide noncoding RNAs that are powerful regulators of gene
expression via targeting of the 3′untranslated region (3′UTR) of specific genes leading to translational repression
or message decay12. With their aberrant expression known to play a pivotal role in the regulation of a variety
of developmental processes and diseases, miRNAs have therapeutic potential for the treatment of cancer and
other illnesses13. Several miRNA-targeted therapies have reached clinical development, including miR-34 (in
the form of a double-stranded miRNA mimic) for treating cancer, and miR-122 (in the form of antimiRs) for
treating hepatitis C
 14,15. There is aberrant miRNA expression in cancer, leading to both inhibition and promotion
of the tumorigenic process, with respective loss of expression of tumor suppressor miRNAs or overexpression of
oncogenic miRNAs (oncomiRs)16–18. In PCa, there has been the identification of miRNA signatures associated
with either poor prognosis or response to therapy, and some have potential functional roles as biomarkers19–24.
These studies emphasize the potential for miRNAs to become cancer therapeutics, and provides an opportunity
to identify downregulated tumor suppressor miRNAs, the replacement of which could be a new strategy in the
treatment of PCa.
Previously, we discovered that miR-642a-5p is a tumor suppressor in PCa25. We showed overexpression of
miR-642a-5p in PCa cells resulted in reduced cell viability, and deoxyhypusine hydroxylase (DOHH) to be a
direct target of miR-642a-5p. DOHH catalyzes the activation of eukaryotic translation initiation factor (eIF5A),
a protein essential for cell growth, and therefore the targeting of DOHH by miR-642a-5p resulted in less eIF5A
activity and a reduction in cell proliferation. Additionally, we found miR-642a-5p to be downregulated in PCa
cell lines or tissue, relative to matched normal cells or tissue, the expression of which was not attributable to the
hyper methylation of its promoter25.
Here, we investigated the mode of action of miR-642a-5p in PCa, and aimed to identify novel downstream
targets of miR-642a-5p, to further understand its effect as a tumor suppressor and potential as a prospective PCa
therapeutic. In an in vivo xenograft model of PCa, transient overexpression of miR-642a-5p potently reduced
tumor growth. RNA-Sequencing (RNA-Seq) analysis of miR-642a-5p treated PCa cells identified dysregulation
of genes that cluster to specific pathways including cancer, cell cycle, organismal injury and abnormalities, and
cellular growth and proliferation. Further, we identified for the first time Wilms Tumor 1 gene (WT1), which is
an oncogene in P
 Ca26,27, as a new direct target of miR-642a-5p in PCa, providing novel insight into the role of
miR-642a-5p as a tumor suppressor in PCa. Taken together, in PCa, miR-642a-5p has broad anti-tumor activity
acting on several tumor pathways, and specifically on genes that regulate proliferation and cell cycle progression.

Results

miR‑642a‑5p inhibits prostate cancer xenograft tumor growth and increases survival. In order

to investigate the effect of miR-642a-5p on PCa cell growth in vivo, we transiently overexpressed miR-642a-5p or
a negative control miRNA (miR-NC) in human 22Rv1 PCa cells (representative of castrate resistant disease28),
and subcutaneously transplanted them into male NOD/SCID gamma (NSG) mice to generate xenografts (10
mice/group). Subsequent to day 25-post injection, we observed a rapid increase in xenograft tumor volume in
the miR-NC mice compared to the miR-642a-5p mice (Fig. 1a). Coronal and axial magnetic resonance imaging (MRI) of animals at 34 days post injection also corroborated the differences in tumor volume observed
between the two groups (Fig. 1b). The end point based on tumor size (1500 mm3) was reached first by mice in
the miR-NC transfected group at day 34 post injection, and all miR-NC xenografts reached end point by day 41
(Fig. 1c). In contrast, only one of the 10 mice in the miR-642a-5p group reached end point at day 41, with the
remainder of the mice in this group progressively reaching end point by day 49 (Fig. 1c). The tumor size-based
survival of the miR-642a-5p treated mice was significantly different to the miR-NC treated mice, as determined
by Log-rank (Mantel-Cox) and Gehan–Breslow–Wilcoxon analyses (p < 0.0001; p < 0.0002, respectively). Taken
together, these data indicate that transient overexpression of miR-642a-5p significantly inhibits PCa xenograft
growth and is associated with increased survival.

RNA‑Sequencing target gene identification and pathway analysis. To explore the mechanism of

miR-642a-5p’s potent inhibition of 22Rv1 PCa xenograft growth, we performed RNA-Seq analysis of 22Rv1 cells
treated with miR-642a-5p or miR-NC (30 nM for 24 h). Using ≥ 0.5 log2 fold change and p < 0.05, we identified
448 genes that were differentially expressed between the two groups; 176 genes were downregulated and 272
were upregulated (Fig. 2a and Supplementary Tables S1 and S2). Of the 176 genes that were downregulated by
miR-642a-5p overexpression, 72 (~ 41%) contained at least one miR-642a-5p seed site (via TargetScan 7.2), and
these genes are listed in Supplementary Table S3. DOHH, which we previously identified as a direct target of
miR-642a-5p, was ranked at the top of Supplementary Table S3 having 6 seed sites and was downregulated 0.69
log2 fold (25 and Supplementary Table S3). Interestingly, of the 272 genes that were upregulated by miR-642a-5p
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Figure 1.  miR-642a-5p inhibits PCa xenograft tumor growth and increases survival. Subcutaneous xenograft
study of 22Rv1 PCa cells transiently overexpressing miR-642a-5p or miR-NC in NSG mice (10 per group). (a)
Xenograft tumor volumes in mice measurable from day 25 to day 34. CI = 0.95; ***p < 0.0002. (b) Coronal and
axial MRI images of day 34 representative mice from both miR-NC and miR-642a-5p xenograft groups. Red
arrows indicate tumor. (c) Tumor size end point Kaplan–Meier survival curve of miR-642a-5p versus miR-NC
xenograft mice. Log-rank (Mantel-Cox) Test ***p < 0.0001, Gehan–Breslow–Wilcoxon Test ***p < 0.0002.
overexpression, 47 (~ 17%) also contained at least one miR-642a-5p seed site, and these genes are listed in Supplementary Table S4 and are putative indirect targets of miR-642a-5p.
To ascertain the major gene networks and biological pathways regulated by miR-642a-5p in 22Rv1 cells, we
performed Gene Set Enrichment Analysis (GSEA) and Ingenuity Pathway Analysis (IPA) of the 448 differentially
expressed genes from the RNA-Seq data. The GSEA analysis identified the KEGG (Kyoto Encyclopedia of Genes
and Genomes)29 pathway ‘DNA replication’ as a significantly depleted gene network following miR-642a-5p
overexpression (Fig. 2b). We identified cancer, cell cycle, organismal injury and abnormalities, and cellular
growth and proliferation as the most significantly enriched biological processes (ranked by the p-value result of
a Fisher’s exact test) with miR-642a-5p treatment (Fig. 2c).

Effect of miR‑642a‑5p on cell cycle progression. To further investigate the effect of miR-642a-5p on

the cell cycle (Fig. 2c), we performed flow cytometry cell cycle analysis of 22Rv1 cells transfected with miR642a-5p or miR-NC, and found that miR-642a-5p induces cell cycle arrest at G0/G1 and a block in transition to
S phase (Fig. 2d). We next overexpressed miR-642a-5p in 22Rv1 cells, and consistent with these cells harboring
wild-type p5330, we observed an increase in the expression of the tumor suppressor cell cycle inhibitors p53
and p21, which supports the observed cell cycle arrest at G0/G1 (Fig. 2e). We then determined if miR-642a-5p
overexpression affects apoptosis, and following annexin V, propidium iodide (PI) staining and flow cytometry,
there was an increase in the apoptotic fraction of miR-642a-5p treated cells, however this difference was not
statistically significant (p > 0.05) (Fig. 2f). Taken together, these data support the notion that mediation of the
growth inhibitory action of miR-642a-5p in 22Rv1 PCa cells is, in part, via alteration of cell cycle progression.

Identification of genes regulated by miR‑642a‑5p and implicated in cell cycle arrest. Further

interrogation of the RNA-Seq data by IPA revealed a number of novel putative cell cycle associated gene targets for miR-642a-5p, which were either significantly (p < 0.05) downregulated or upregulated ≥ 0.5 log2 fold.
Downregulated genes included WT1, NUAK1 [NUAK family SNF1-like kinase 1; also known as AMPK-related
protein kinase 5 (ARK5)], RASSF3 (Ras association domain family member 3), and SKP2 (S-phase kinaseassociated protein 2), and are indicated in green in Fig. 3a. Conversely, GPS2 (G Protein Pathway Suppressor
2; also known as AMF1) and IGFBP3 (Insulin-like growth factor-binding protein 3) indicated in red in Fig. 3a
were upregulated by miR-642a-5p in the RNA-Seq and are all associated with G0/G1 arrest (IPA). We further
validated these findings by transiently overexpressing miR-642a-5p or miR-NC in 22Rv1 cells and measured the
mRNA expression of these cell cycle genes. The expression of WT1, NUAK1, RASSF3, and SKP2 were all downScientific Reports |
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Figure 2.  miR-642a-5p targets genes and pathways involved in DNA replication and cell cycle arrest. (a)
Volcano plot of RNA-Seq results, with green dots representing genes downregulated, and red dots representing
genes upregulated (≥ 0.5 log2 fold change; p < 0.05) by miR-642a-5p. (b) Gene Set Enrichment Analysis (GSEA)
of the RNA-Seq data. The y-axis and the green line show the enrichment score for each gene, illustrated as a
vertical line plotted in rank order of the most gene abundance (red, left) to the least gene abundance (blue, right)
within the indicated samples (as log2FC/comparison); the black vertical lines correspond to member genes
from the set. NES normalized enrichment score, FDR false discovery rate. (c) Ingenuity Pathway Analysis of
the miR-642a-5p up and downregulated genes. Pathways ranked by the p value result of a Fisher’s exact test. (d)
Flow cytometry cell cycle analysis of 22Rv1 cells transfected with miR-642a-5p or miR-NC (30 nM) for 72 h.
n = 3; *p < 0.05, **p < 0.005 relative to miR-NC. (e) Western blot analysis of p21 and p53 protein expression 72 h
post-transfection of 22Rv1 cells with 30 nM miR-642a-5p or miR-NC. β-actin is the loading control. Bands are
from non-adjacent lanes of the same western blot and are separated by white space (see Supplementary Fig. S1A
for uncropped blots, which were cut into smaller strips prior to immunoblotting). n = 3. (f) Flow cytometry
apoptosis analysis of 22Rv1 cells transfected miR-642a-5p or miR-NC (30 nM) for 72 h. Error bars = SD; n = 3;
p > 0.05.
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Figure 3.  Cell cycle arrest gene targets of miR-642a-5p. (a) Ingenuity Pathway Analysis of cell cycle targets
of miR-642a-5p. Green denotes genes downregulated by miR-642a-5p, and the number of seed sites in their
3’UTR (identified by TargetScan 7.2) indicated. Red denotes genes upregulated by miR-642a-5p. (b) RT-qPCR
analysis of the cell cycle genes following overexpression of miR-642a-5p in 22Rv1 PCa cells. Expression of target
mRNAs is normalized to HPRT housekeeping gene expression, calculated using the 2 −ΔΔCt method, and relative
to miR-NC. Error bars = SE; n = 3; *p < 0.05 relative to miR-NC. (c) Oncomine analysis of the expression of the
miR-642a-5p targets in PCa data sets. (i) WT1; (ii) NUAK1; (iii) RASSF3; (iv) SKP2; (v) IGFBP3; and (vi) GPS2.
The data cohorts indicated above each graph, and n per group shown. Boxes denote the median (horizontal
line); whiskers indicate distances to the highest and lowest values [for NUAK1 and RASSF3 the lower whisker is
to the 10th percentile (minimum value removed)]. *p < 0.05, **p < 0.005.
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Figure 4.  WT1 is a direct target of miR-642a-5p in PCa cells. (a) The 3′UTR of WT1 has three putative miR642a-5p seed sites as predicted by TargetScan 7.2. (b) Schematic of the 3′UTR of WT1 (not to scale). Depiction
of the GeneCopoeia target clone, which contains only the first 1293 base pairs of the 3′UTR, is with green
shading. The grey shaded boxes indicate the miR-642a-5p seed sites. (c) Luciferase reporter gene analysis of the
3′UTR of the putative miR-642a-5p target WT1 in 22Rv1 and LNCaP PCa cells transiently overexpressing miR642a-5p or miR-NC (20 nM). DOHH and miR-642a-5p perfect targets are positive controls. Error bars = SD;
n = 3; **p < 0.005.
regulated, and the expression of IGFBP3 was upregulated following miR-642a-5p treatment (Fig. 3b). There was
no significant difference in GPS2 mRNA levels following miR-642a-5p overexpression (data not shown). Taken
together, these data support the regulation of cell cycle genes as a key proposed mechanism of miR-642a-5p
action in PCa cells.

Clinical impact of the miR‑642a‑5p cell cycle targets. To explore the potential clinical impact of
these data we used Oncomine analysis to interrogate various PCa datasets and compared the gene expression of
our miR-642a-5p targets between normal prostate and PCa samples. Examination of these cohorts revealed that
each of the downregulated miR-642a-5p target genes (WT1, NUAK1, RASSF3, and SKP2) is a potential driver
of tumor progression, as each of their expression levels was higher in prostate tumor samples when compared
to normal prostate tissue (Fig. 3c i–iv). Conversely, both IGFBP3 and GPS2, which were upregulated with miR642a-5p overexpression in RNA-Seq, had lower levels of expression in the PCa samples (Fig. 3c v and vi). This
data suggests that miR-642a-5p coordinately regulates (either up or down) a range of genes, with the net result
of substantially decreasing PCa cell growth.
Validation of WT1 as a direct target of miR‑642a‑5p.

There is increasing evidence suggesting that
WT1 functions as an oncogene in PCa26, and given its involvement in cell cycle progression27, the existence of
three miR-642a-5p seed sites within its 3′UTR (Fig. 4a and Supplementary Table S3), and its clinical impact
[Fig. 3c(i)], we chose to evaluate WT1 further as a target of miR-642a-5p. To ascertain whether WT1 is a direct
target of miR-642a-5p, we transiently co-transfected a luciferase reporter construct containing the first 1293
base pairs (bp) of WT1’s 3′UTR region (total length 5146 bp) (Fig. 4b), along with miR-642a-5p or miR-NC into
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22Rv1 and LNCaP PCa cells. Transfection of miR-642a-5p significantly (p < 0.005) downregulated the luciferase
reporter activity of WT1 3′UTR in both of the PCa cell lines validating the direct targeting of miR-642a-5p
(Fig. 4c). As positive controls, we included the DOHH 3′UTR construct, as well as a reporter containing the perfect target sequence for miR-642a-5p25. Together with the TargetScan prediction of three seed sites, this data is
the first evidence supporting the concept that WT1 is a direct target of miR-642a-5p, and therefore an important
downstream target of miR-642a-5p.

Targeted siRNA knockdown of WT1 reduces cell proliferation and blocks cell cycle progres‑
sion. We next used small interfering RNA (siRNA) to transiently knockdown WT1 gene expression in 22Rv1

and LNCaP PCa cells, to assess the functional effects of WT1 on PCa growth. We initially tested four different
WT1 siRNAs in 22Rv1 cells, and RT-qPCR quantitation confirmed an approximate 80% reduction in WT1
expression with the ‘WT1#8’ siRNA, as compared to negative control siRNA (si-NC) (Supplementary Fig. S2A).
We subsequently used WT1#8 siRNA in our experiments, and in each instance validated WT1 knockdown via
RT-qPCR (Supplementary Fig. S2B–E). We transiently transfected 22Rv1 and LNCaP cells with either WT1
siRNA or si-NC and assessed cell proliferation using a Cell Titer end-point assay or the xCELLigence real time
system. WT1 siRNA transfected cells exhibited a substantial growth reduction as compared to the si-NC transfected cells using both methods of evaluation (Fig. 5a, b). Furthermore, siRNA-mediated knockdown of WT1
reduced colony formation in clonogenicity assays (Fig. 5c). We also performed flow cytometry cell cycle analysis
of 22Rv1 and LNCaP PCa cells transfected with WT1 siRNA or si-NC, and found that WT1 knockdown induced
cell cycle arrest at G0/G1, and a concurrent increase in p21 and p53 expression (Fig. 5d, e). Additionally, treatment of 22Rv1 and LNCaP PCa cells with a combination of both WT1 siRNA and a clinically available inhibitor
of WT1 (Tanespimycin (17-AAG [17-(allylamino)-17-demethoxygeldanamycin]), resulted in a further reduction of cell growth than with WT1 siRNA or 17-AAG alone (Fig. 5f). Taken together, these data suggest that
therapeutic targeting of WT1 in PCa could be beneficial for tumor growth inhibition.

Overexpression of WT1 increases colony formation and miR‑642a‑5p rescues this effect. To
further investigate the anti-cancer contribution of WT1 targeting by miR-642a-5p, we transiently and stably
overexpressed WT1 cDNA (WT1-203 isoform) in 22Rv1 and LNCaP PCa cells, and transfected these cells with
30 nM miR-642a-5p or miR-NC. RT-qPCR analysis validated the stable or transient WT1 overexpression, and
subsequent miR-642a-5p treatment significantly downregulated WT1 expression (Fig. 6a). Overexpression of
WT1 in 22Rv1 PCa cells resulted in an increase in colony formation in clonogenicity assays, an effect which was
rescued with miR-642a-5p overexpression (Fig. 6b). Taken together, miR-642a-5p replacement in 22Rv1 and
LNCaP PCa cells with ectopic overexpression of WT1 significantly ‘rescues’ its anti-cancer effects on WT1 gene
targeting, further suggesting miR-642a-5p could be an ideal therapy in PCa.

Discussion

There have been numerous reports regarding the molecular signatures and functions of specific microRNAs
in cancer, and there are important opportunities to identify tumor suppressor m
 icroRNAs15,31–33. There is little
known about the functional role of miR-642a-5p and cancer, and here we characterize its mode of action as a
tumor suppressor in 22Rv1 and LNCaP PCa cells, both being models of C
 RPC34. Overexpression of miR-642a-5p
resulted in a considerable decrease in xenograft tumor growth in vivo, and its overexpression dysregulated
genes involved in DNA replication and cell cycle progression. Further, the expression of the cell-cycle-regulated
genes which were either downregulated (e.g. WT1, NUAK1, RASSF3, and SKP2) or upregulated (e.g. GPS2 and
IGFBP3) by miR-642a-5p in PCa were inversely related to the effect of the miRNA; those genes downregulated
by miR-642a-5p were upregulated in tumor compared to normal prostate and vice versa, further supporting
miR-642a-5p as a tumor suppressor microRNA. Additionally, our data suggest that direct therapeutic targeting
of the miR-642a-5p cell cycle target genes, in particular WT1, could produce significant anti-tumor effects to
benefit PCa patients.
We first described miR-642a-5p as a tumor suppressor in PCa25, and indeed, there are few studies exploring
the role of miR-642a-5p in cancer. In one report, expression of miR-642a-5p was downregulated in colon cancer
cell lines and tumor tissue compared to normal, and overexpression of miR-642a-5p reduced the growth of colon
cancer cell lines in vitro and in vivo35, further supporting our observations of miR-642a-5p as a tumor suppressor. Interestingly, also in colon cancer, the long non-coding RNA LINC01234 and the circular RNA-103809 have
been shown to act as competing endogenous RNAs (ceRNA) or ‘sponges’ of miR-642a-5p, thereby reducing its
bioavailability and tumor suppressive f unctions35,36. Additionally, the expression of miR-642a-5p was reduced in
colorectal cancer cells, in peripheral immune cells following resection of lung tumors, and in childhood hematological cancers suggesting a potential biomarker role of miR-642a-5p in the diagnosis of these cancers37–39.
Another recent report demonstrated a tumor suppressive function of miR-642a in liver cancer (hepatocellular
carcinoma (HCC)); miR-642a expression was decreased, which enabled increased SEMA4C expression and
signaling via the p38 MAPK pathway40. Also in HCC, Tang and colleagues showed miR-642 to be a tumor suppressor ceRNA, via interacting with, and disrupting the oncogenic functions of Linc00974 and K
 RT1941. In a
study investigating advanced bladder cancer, expression of miR-642a-5p was reduced in patient tumors, and
transient overexpression of miR-642a-5p mimics in bladder cancer cells in vitro reduced their viability, consistent with a tumor suppressor role42. Taken together, these studies provide increasing evidence that miR-642a-5p
is a potent tumor suppressor across several cancer types.
Dysregulation of cell cycle and its control underpins cancer biogenesis and its capacity to p
 roliferate43. Our
data demonstrate that miR-642a-5p overexpression regulates a coordinated set of genes that drive cell cycle arrest
at the G0/G1 (proliferation or quiescence) phase, and support cell cycle arrest as a proposed key mechanism of
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Figure 5.  Targeted siRNA-mediated inhibition of WT1 expression reduces PCa cell proliferation and blocks cell
cycle progression. (a) Relative cell viability of 22Rv and LNCaP PCa cells measured via cell titer assay at 3 d posttransfection with WT1 siRNA or si-NC (20 nM). Validation of WT1 knockdown see Fig. S2B. Error bars = SD; n = 3;
**p < 0.005. (b) Proliferation of 22Rv1 and LNCaP PCa cells (cell index) measured using the xCELLigence system post
WT1 siRNA or si-NC transfection (20 nM). Validation of WT1 knockdown see Fig. S2C. Error bars = SD; n = 3. (c)
Colony formation assay of 22Rv1 and LNCaP PCa cells 14–21 days post WT1 siRNA or si-NC (20 nM) transfection.
Validation of WT1 knockdown see Fig. S2C. Error bars = SD; n = 3; **p < 0.005. (d) Flow cytometry cell cycle analysis of
22Rv1 and LNCaP PCa cells transfected with WT1 siRNA or si-NC (20 nM) for 72 h. Validation of WT1 knockdown
see Fig. S1D. n = 3; *p < 0.05, **p < 0.005 relative to si-NC. (e) Western blot analysis of p21 (22Rv1 and LNCaP) and p53
(22Rv1) protein expression 72 h post-transfection of PCa cells with 20 nM WT1 siRNA or si-NC. β-actin is the loading
control. Validation of WT1 knockdown see Fig. S2E. For full-length, non-cropped blots see Fig. S1B and S1C. n = 3. (f)
Relative cell viability of 22Rv1 and LNCaP PCa cells measured via cell titer assay at 5 days post-transfection with WT1
siRNA or si-NC (20 nM), and 3 d post-17-AAG treatment (1 µM). Validation of WT1 knockdown see Fig. S2B. Error
bars = SD; n = 3; **p < 0.005.
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Figure 6.  WT1 overexpression increases colony formation and miR-642a-5p rescues this effect. (a) RT-qPCR
analysis of WT1 gene expression following stable or transient LeGO-iT2-WT1-203 or LeGO-iT2-Empty
plasmids, and overexpression of miR-642a-5p or miR-NC in 22Rv1 and LNCaP PCa cells. Expression of WT1 is
normalized to HPRT housekeeping gene expression, calculated using the 2 −ΔΔCt method, and relative to Empty
vector + miR-NC. Error bars = SE; n = 3; *p < 0.05, **p < 0.005 relative to Empty vector + miR-NC. #p < 0.05 WT1203 + miR-NC relative to WT1-203 + miR-642a-5p. (b) Colony formation assay of 22Rv1 PCa cells 14 days post
transient WT1 overexpression/empty vector transfection and miR-NC/miR-642a-5p (30 nM) co-transfection.
Error bars = SD; n = 3; **p < 0.005 relative to Empty vector + miR-NC. ##p < 0.005 WT1-203 + miR-NC relative to
WT1-203 + miR-642a-5p.
miR-642a-5p action. Cyclin-dependent kinases (CDKs) are critical enzymes that promote transition through
the cell cycle and hence the targeting of these in proliferating cancer cells has been the basis for development
and clinical application of novel anticancer t herapies43–45. The CDK inhibitors p21 and p53 are known tumor
suppressors and play key roles in regulating transition of cells through the cell c ycle46. Our data showing their
upregulation following miR-642a-5p overexpression also support the role of miR-642a-5p as a tumor suppressor in PCa. Interestingly, miR-642a-5p’s ability to reduce cell viability of PCa cells is not reliant on cellular p53
status, as our previous study using other PCa cell subtypes which harbour non-functional p53 (e.g. DU145) also
showed a reduction in cell viability with miR-642a-5p o
 verexpression25,30.
Wilms Tumor 1 (WT1) gene is a member of the early growth response gene I (EGR-1) family of zinc finger
transcription factors, having an important role in the normal development of the genitourinary system and other
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organs and t issues47,48. In addition to the requisite role of WT1 in development, it also plays a complex role in
tumorigenesis, acting as either a tumor suppressor or an oncogene depending on the cellular c ontext47,48. There
is mounting evidence that WT1 functions as an oncogene in PCa, acting by facilitating the development of a
lethal metastatic phenotype26,27. In addition, WT1 expression is elevated in high-grade PCa tissues, and the level
of expression may serve as a biomarker for PCa progression49. Furthermore, administration of 17-AAG, a clinically available inhibitor of WT1 (via its interaction with heat shock protein 90), was shown to decrease myeloid
leukemia xenograft growth, correlating with decreased expression of WT1 and its downstream targets50. Our
data suggests WT1 is a direct target of miR-642a-5p, and siRNA or 17-AAG targeting of WT1 reduced cellular
proliferation in 22Rv1 and LNCaP PCa cells. Furthermore, when WT1 was overexpressed in 22Rv1 and LNCaP
cells miR-642a-5p overexpression effectively reduced WT1 gene expression and colony formation. These data,
together with our TCGA Oncomine data, support the concept that therapies targeting WT1, such as miR-642a-5p
replacement treatment or 17-AAG, could reduce PCa growth and potentially represent treatment alternatives.
The other putative miR-642a-5p target genes, which are associated with cell cycle, have roles as oncogenes
or tumor suppressors in cancer. SKP2, which is overexpressed in P
 Ca51, plays a critical role in cancer development by controlling several cellular processes such as cell cycle regulation and cell proliferation, by degrading
specific CDK inhibitors52,53. Overexpression of NUAK1 is associated with poor prognosis in many cancers,
including colorectal, ovarian, and lung54–56. There is growing evidence showing NUAK1 is a target of multiple
miRNAs, whose expression is frequently decreased during cancer progression to metastatic d
 isease57. Addi58
tionally, NUAK1 is a positive regulator of cell cycle progression in breast cancer cells . Our data supports the
oncogenic function of SKP2 and NUAK1 in PCa, as their targeted degradation by miR-642a-5p resulted in cell
cycle arrest. Conversely, RASSF3 functions as a tumor suppressor through stabilization of p53 and regulation of
apoptosis and G1-S cell cycle a rrest59, its downregulation increases malignant phenotypes of non-small cell lung
cancer60, and is, in part, responsible for resistance to mammary tumor development in Neu transgenic mice61.
These reports are contradictory to our observation of RASSF3 targeting by miR-642a-5p for inhibition of cell
cycle progression in PCa, and coupled with the Oncomine TCGA data showing a higher level of RASSF3 in PCa
tissue, suggests RASSF3 function may be dependent on cellular context. We found miR-642a-5p overexpression
upregulated IGFBP3 and GPS2 expression. This data is consistent with previous reports; IGFBP3 overexpression has been shown to induce cell cycle arrest at G1 phase in breast cancer62 and suppress metastasis in PCa63,
and GPS2 overexpression in osteocarcinoma was associated with cell cycle a rrest64. Taken together, these data
provide strong support for miR-642a-5p functioning as a potent tumor suppressor in PCa, an effect mediated by
a coordinated change in expression of multiple targets leading to significant impact on cell cycle. We have previously studied other microRNAs, including miR-7-5p65 and miR-331-3p24, and identified multiple coordinately
regulated downstream targets and signaling pathways, with a net effect of potent tumor inhibition, similar to
what we identified herein.
There is an urgent need for new therapies for men with advanced PCa. Our data suggests miR-642a-5p is
a potent PCa tumor suppressor in vitro and in vivo and that its successful replacement into PCa tissue could
represent a new avenue of therapy for this disease. This is particularly relevant given that the field of RNA-based
therapeutics is undergoing rapid change. With the recent approval of multiple siRNA drugs by the U.S. Food
and Drug Administration there is an increased interest in using double stranded RNAs, including miRNAs, as
therapies to treat human disease15,66,67. In that context, our data provides a foundation for further work to develop
miR-642a-5p into an RNA-based PCa therapeutic.

Methods

All the experimental protocols were performed in accordance with institutional guidelines and regulations of
the Harry Perkins Institute of Medical Research.

Cell culture, miRNA precursors, luciferase reporter constucts, siRNA molecules, small mol‑
ecule inhibitors and cDNA expression constructs. 22Rv1 and LNCaP PCa cells were obtained from

the American Type Culture Collection (ATCC) and cultured at 37 °C/5% CO2 in RPMI-1640 supplemented
with 10% fetal bovine serum (FBS). Synthetic miRNA molecules corresponding to human miR-642a-5p (hsamiR-642a-5p; Cat #AM17100, Product ID: PM11477) and a negative control miRNA (miR-NC; Negative Control #1, Cat# AM17110) were sourced from Ambion (Thermo Fisher Scientific). The miRNA 3′UTR luciferase
reporter constuct for WT1 (#Hmi T058379-MT06) was generated by GeneCopoeia (Rockville, MD). The miR642a-5p perfect target and DOHH 3′UTR reporter constructs were generated by GenScript, Inc (Piscataway), as
described25. Flexitube siRNAs to WT1 were from Qiagen (WT1#1 Cat#SI00008267; WT1#4 Cat#SI00008288;
WT1#7 Cat#SI03056298; and WT1#8 Cat#SI03061331). The negative control siRNA (si-NC) was from Ambion
(Cat#4390843). Tanespimycin (17-AAG) was from Selleckchem (Cat#S1141). Human WT1 cDNA (WT1-203,
ENST00000379079.8, Ensembl) was synthesized (GenScript) and cloned into LeGO-iT2 lentiviral vector (a gift
from Boris Fehse, Addgene plasmid # 27343).

PCa cell xenograft model and tumor imaging. 22Rv1 cells were transfected using Lipofectamine 2000
(Thermo Fisher Scientific) with 50 nM miR-642a-5p or miR-NC. At 72 h post transfection cells were trypsinized,
counted, and 1.5 × 106 cells in 150 µL of a 1:1 dilution of RPMI-1640 and Matrigel (BD BioSciences) was injected
subcutaneously into male NSG mice (Animal Resource Centre, Western Australia) (10 per group). Generation
of T2 weighted coronal and axial MRI images of NSG mice were by a 3.0 T MRS 3000 preclinical MRI system at
the Australian Cancer Research Foundation Cancer Imaging Facility at the Harry Perkins Institute of Medical
Research, Perth, Australia. All the experimental protocols were approved by the Harry Perkins Institute of Medical Research animal ethics committee (AE048/2016). All methods used for animal experimentation were carried
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out in accordance with the relevant guidelines and regulations of the Harry Perkins Institute of Medical Research
Animal Ethics Committee. All animal work was carried out in compliance with the ARRIVE guidelines (http://
www.nc3rs.org.uk/page.asp?id=1357).

RNA‑Sequencing expression profiling and analysis. For the RNA-Seq study, triplicate wells of 22Rv1
cells were transfected using Lipofectamine 2000 with 30 nM miR-642a-5p or miR-NC, and total RNA extracted
from the samples 24 h post-transfection, using the Isolate II RNA kit (Bioline) according to the manufacturer’s
instructions. The quantity and integrity of extracted RNA was determined using a 2100 Bioanalyzer (Agilent
Technologies), before RNA-Seq analysis using the Illumina HiSeq 2500 at the Australian Genome Research
Facility (AGRF; Victoria, Australia). Analysts at AGRF normalized the data with the R Bioconductor ‘EdgeR’
package (www.Bioconductor.org). Briefly, sequence counts were aligned to the genome, background corrected,
log2 transformed, annotated, and a fold change analysis performed to compare treatment groups.
TargetScan (Version 7.2: March 2018) provided metadata on genes downregulated by miR-642a-5p in the
RNA-Seq experiment. Gene Set Enrichment Analysis (GSEA) of the RNA-Seq data was performed as previously
described68. The biological pathway targets of genes differentially expressed by miR-642a-5p were determined
using Ingenuity Pathway Analysis (IPA, Ingenuity System, Inc. www.qiagenbioinformatics.com/products/ingen
uity-pathway-analysis). The RNA-Seq data is available in the Gene Expression Omnibus under Accession Number GSE160736.
Cell cycle analysis. 22Rv1 or LNCaP PCa cells were transfected as described above with 30 nM miRNA

(miR-642a-5p or miR-NC), or 20 nM siRNA (WT1 siRNA or si-NC) molecules. Following treatment for 72 h,
floating and adherent cells were collected, fixed with cold 100% ethanol and stored at 4 °C. Fixed cells were
stained with Propidium Iodide (PI) staining solution (25 µg/ml PI and 0.25 µg/ml RNase A in PBS), and analysed using the BD Accuri C6 Flow Cytometer and FlowJo Software (version 7.6.5), and the Dean-Jett-Fox
method for gating cells.

Annexin V‑FITC/PI apoptosis assay. 22Rv1 cells were transfected as described above with 30 nM miR642a-5p or miR-NC for 72 h, or treated with 10 µM Camptothecin (Cayman Chemical) for 24 h (positive control
for apoptosis). Apoptosis was measured using the Annexin V-FITC Apoptois Detection Kit I (BD Biosciences,
NSW, Australia), using the manufacturer’s instructions. No stain, single stain and camptothecin treated cells
were used to set gating strategies to identify live, apoptotic and dead cell populations. Samples were analysed
using the BD Accuri C6 Flow Cytometer and software.
Generation of 22Rv1 and LNCaP stably overexpressing WT1 cell lines. 22Rv1 and LNCaP PCa
cell lines stably expressing WT1-203 cDNA were generated by lentiviral transduction as previously d
 escribed69,70.
Briefly, 22Rv1 and LNCaP cells were infected with lentiviruses carrying LeGO-iT2-Empty or LeGO-iT2WT1-203 plasmids, and transduced cells stably expressing tdTomato fluorescent protein were isolated by flow
cytometry (FACSCalibur, BD Biosciences). The ectopic expression of WT1 in the isolated cells was validated
with RT-qPCR.
Transfection of miRNA precursors, siRNA molecules, cDNA overexpression constructs, and
reporter gene assays. Parental 22Rv1 and LNCaP PCa cells, or 22Rv1 and LNCaP cells with stable expres-

sion of LeGO-iT2-WT1-203 or LeGO-iT2-Empty plasmids were seeded into 6-well plates or 10 cm diameter dishes and transfected as described above with miRNA or siRNA molecules at a final concentration of
10–30 nM. Cells were harvested 24 h post-transfection for RNA isolation and 3 days for protein extraction. For
transient WT1 overexpression, 5 ng of LeGO-iT2-WT1-203 or LeGO-iT2-Empty plasmids were cotransfected
with 10–30 nM miRNA molecules, and RNA and protein isolated at 2 and 3 days post-transfection, respectively.
For Luciferase reporter gene assays 22Rv1 and LNCaP cells were seeded into 6-well plates and co-transfected
with 450 ng of firefly luciferase reporter plasmid DNA and 10 nM final concentration of either miR-642a-5p
or miR-NC, using Lipofectamine 2000. After 48 h, lysates were assayed for firefly luciferase activity using the
Luciferase Reporter Assay System (Promega) and a Fluostar OPTIMA microplate reader (BMG Labtech).

Cell proliferation and colony forming assays. Parental or WT1-overexpressing 22Rv1 and LNCaP
PCa cells were transfected in 10 cm dishes with miRNA molecules, siRNAs, or cDNA plasmid constructs (as
described above). One day post-transfection, the cells were trypsinized and plated into 96 well plates, xCELLigence E-plates at 5000 cells/well, or into 10 cm dishes at 5000 cells (22Rv1) or 10,000 cells (LNCaP)/dish.
Proliferation was evaluated in the 96 well plates at 1–7 days post-seeding using a CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) and the Fluostar OPTIMA microplate reader, according to the manufacturer’s instructions. Treatment with 17-AAG (1 µM) was 24 h post-seeding, and proliferation evaluated 1–7 days
later using the same assay (Promega). The xCELLigence system (In Vitro Technologies) was used to measure the
proliferation of cells in a real time setting for 72 h, according to the manufacturer’s instructions. The cells which
were plated into the 10 cm dishes were assayed for colony formation after 2–3 weeks, using Crystal Violet staining as previously described65.
RNA extraction, reverse transcription and quantitative polymerase chain reaction
(RT‑qPCR). Total RNA was extracted from 22Rv1 and LNCaP PCa cells 24 h post-transfection with miRNAs or siRNAs, using TRIzol reagent as per the manufacturer’s instructions (Thermo Fisher Scientific). RNA
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was quantitated using the NanoDrop One spectrophotometer and 800 ng RNA was reverse transcribed using
a QuantiTect reverse transcription kit (Qiagen). Quantitative PCR was performed in a Rotor-Gene Q thermocycler (Qiagen) using Bioline SensiMix (QT605-20) and validated QuantiTect primers (Qiagen) for HPRT1
(Cat#QT00059066, housekeeping control), WT1 (Cat#QT00059003), NUAK1 (Cat#QT00097447), RASSF3
(Cat#QT00051044), SKP2 (Cat#QT00006489), IGFBP3 (Cat#QT00072737), or GPS2 (Cat#QT00050715). For
the WT1 overexpression experiments, the following primers from Sigma were used: WT1-exon8 (F) GTGACT
TCAAGGACTGTGAACG; and WT1-exon9 (R) CGGGAGAACTTTCGCTGACAA.
Expression of target mRNAs relative to HPRT expression was calculated using the 2 −ΔΔCt method71.

Protein extraction and western blotting.

Protein extracts were prepared from cells lysed with midRIPA buffer and western blotting performed as described24. Briefly, protein samples were resolved in NuPAGE
4–12% Bis Tris gels (Thermo Fisher Scientific) and transferred to PVDF membranes (Roche). Membranes were
blocked in Tris-buffered saline/Tween 20 (TBST)/5% skim milk and incubated with p21 (Cell signaling #2947S;
1:1000), p53 (Cell signaling #9282S; 1:500, or Santa Cruz #SC-126; 1:1000), or β-actin [AC-15] (Abcam ab6276;
1:5000) primary antibodies, followed by incubation with horseradish peroxidase (HRP) linked secondary antibodies [anti-mouse IgG (GE Healthcare; Cat#NA931V) or anti-rabbit IgG (GE Healthcare; Cat#NA934V)]. Protein detection was with enhanced chemiluminescence (ECL) using Luminata Classico Western HRP substrate
(Millipore #WBLUC0100), and visualization was with either ECL-Hyperfilm (GE Healthcare; #GE HE28-906837) or the iBright Imaging System (Thermo Fisher Scientific).

Clinical datasets.

Oncomine (www.oncomine.org) analyses determined the differential expression levels of
WT1, NUAK1, RASSF3, SKP2, IGFBP3, and GPS2 between normal and tumor prostate tissue cohorts from The
Cancer Genome Atlas (TCGA), Tomlins, Taylors Prostate 3 or Yu Prostate data sets.

Statistical analysis. Graphing and analysis of data was with GraphPad Prism 8 software. Use of the

unpaired t-test (two-tailed) determined significant differences between clinical datasets in Oncomine, luciferase
reporter assays, RT-qPCR assays, cell cycle analysis and apoptosis. Use of a two way ANOVA with repeated
measures determined significant differences between PCa xenograft volumes. Log-rank (Mantel-Cox) and
Gehan-Breslow-Wilcoxon testing was used for determining significant differences between xenograft survival
curves. IPA molecular pathway analysis package used a Fisher’s exact test on genes identified by RNA-Seq.
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